

INDEX

- Abe (Kyoto legal scholar), 165
 Abe, Shinzo, 157, 159, 250
 abortion, 102
 Academia Japan, 168–169
 Academia, Business and Clinical approach, 227
 Academies of Military Medical Sciences (AMMS), 73, 76
 Accelerated Approval Program, 114
 acceleration. *See* regulatory acceleration
 acceptable science, 27, 44, 52, 82, 147
 access to treatment, 114–115, 238
 acquisitive desire, 26, 213
 caring solidarity and, 269–271
 social contract and, 243
 acquisitive imitation, 264
 Act for the Promotion of Regenerative Medicine (Japan), 158
 Act on the Safety of Regenerative Medicine (RM Act) (2013), 58, 158, 166, 169
 fatalities and, 234
 GMP and, 173
 international brokerage and, 225
 regulatory immunity and, 240
 JSRM and, 222
 Taiwan and, 236
 active brokerage, 210–212, 216, 219, 221, 238–239
 forms of, 217
 Adams, Rachel, 270
 imitative desire and, 264
 adaptive licensing, 236
 ADIPOA1, 119
 Administrative Measures for Clinical Research for Stem Cells (Trial Implementation) (CFDA 2015), 68, 237–238, 282
 Advanced Medical Treatment status (Japan), 159
 Advanced Regenerative Medicine and Biopharmaceutical Safety and Support Act (2019), 233
 Advanced Therapy Medicinal Products (ATMP), 50, 118–120
 adverse trial effects, 106, 117, 179
 advertising, 117
 affordability, 104, 121
 alternative regulation and, 252
 political desire and, 105
 R-CPX and, 136–137
 agency, 23
 lateral political pressures and, 215
 regulatory capitalism and, 64
 regulatory discrepancy and, 208
 Agency for Medical Research Development (AMED), 158, 165, 178, 238
 global brokerage and, 229–230
 industrial investment and, 252
 age-related macular degeneration (AMD), 163, 166, 170, 178
 state investment and, 250
 Agreement on Trade Related Investment Measures (TRIMS), 11
 AIFA (Italian Medicine Agency), 120
 Ali, Robin, 251
 All Japan System (AJS), 30, 155–156, 159–162, 169–171, 174–177
 approval-mechanisms and, 178–180
 collaboration and, 163–165
 funding and, 178–180

- All Japan System (AJS) (cont.)
 - funding overhaul and, 159
 - iPSC research and, 165–169
 - misrecognition and, 177–178
 - politics and, 163
 - scientific constraints and, 163–174
 - vision of, 178
- alleviation of suffering, 266
- Alliance for Harmonization of Cellular Therapy Accreditation (AHCTA), 60
- Alliance for Regenerative Medicine (ARM), 230, 232
 - formulation of regulations and, 45
 - Japan and, 151
- allogeneic stem cell therapy, 11
 - AJS and, 170–171
 - Australia and, 116
 - Category-3 drugs and, 70
 - CiRA and, 170
 - immune suppressants and, 176
 - Stempeutics and, 81–83, 85
 - transfusion and, 173
- alternative medicine, 2, 63
 - Beike and, 111
 - health activism and, 204
- alternative regulation
 - affordability and, 252–253
 - credible authority and, 97
 - Guangzhou Alliance and, 75
 - regulatory brokerage and, 64
 - regulatory immunity and, 106
- Alzheimer's Disease, 234
- Amcell, 72
- American Association of Blood Banks (AABB), 61, 109, 111
- An Yihua, 73
- Anspach, Mark, 96, 259–260
- anything goes attitude, 65
- Arendt, Hannah, 9
- Asia
 - AJS and, 160, 164–165
 - fraudulent providers and, 41
 - global brokerage and, 230
 - HOs and, 186, 195
 - individual-rights discourses and, 202–203
 - IOMD and, 183
 - Japanese–Thai collaboration and, 132
 - patient populations and, 261
 - regulatory harmonisation and, 144
 - regulatory overhaul and, 42
 - stem cell tourism and, 182
 - unreliability and, 37
- Asia Partnership Conference of Regenerative Medicine Associations, 230
- Asian Cellular Therapy Organization (ACTO), 236
- Asian financial crisis of 1987, 36
- Asian Stem Cells, 57
- Asian Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs, 230
- assays (iPSCs), 167–169, 175–176
- Association of Southeast Asian Nations (ASEAN), 134, 141
 - regulatory capital and, 145
 - Thai Revised Drug Act and, 144
- Astro Stem, 234
- Athersys, 59
- AusBiotech Regenerative Medicine Advisory Group (RMAG), 117
- Australia, 116–118
 - caring solidarity and, 241
 - EU and, 120
 - regulatory reputation and, 121
- Auto-Culture®, 129, 143
- autologous stem cell therapy, 11–12
 - Australia and, 116–117
 - caring solidarity and, 241
 - Crohn's and, 255
 - HICs and, 112
 - Parkinson's Disease and, 170
 - pay-to-participate and, 115
 - regulatory immunisation and, 122
 - same surgical procedure exception and, 114
 - Takahashi pilot study and, 170
- automation, 128–130, 143, 227. *See also* Japanese–Thai collaboration
- AveXis, 249
- Ayurveda, 192

- Bayh-Dole Act (US), 159
- BaYi Brain Hospital, 73
- Beijing University, 109
- Beike Biotechnology Company, 29, 56–57, 108–112
 - ICMS and, 61
 - patient ethics and, 111–112
 - stem cell tourism and, 102
 - universal regulation and, 122
- Bell, Catherine, 25
 - regulatory redemption and, 153
- Bharadwaj, Aditya, 103
- Bianco, Paolo, 104
- bilateral organisation, 217, 228
- biliary cirrhosis, 70
- bioethics, 16–18, 23
 - acceptable science and, 44, 94
 - Beike patients and, 111–112
 - caring solidarity and, 271
 - hegemony and, 69
 - local considerations and, 151
 - markets and, 96
 - practice of, 76
 - rational individualism and, 263
 - recklessness and, 102
 - regulatory immune-tolerance and, 95
 - scientific integrity and, 101
 - scientific uncertainty and, 99
 - socio-political positions and, 152
 - toeing the regulatory line and, 76
 - unethical binary with, 123
 - universal application of, 106
 - universal appraisals of, 105, 107
- ‘Bioethics Briefing Note’ (UK Nuffield Council), 17
- biologics, 114
 - Australia and, 116–117
 - regulatory immunisation and, 121
 - South Korea and, 233
- Biologics License Applications (BLAs), 51
- biology, 43
 - conceptual uses of, 92
- biomedical platform theory, 66
- biomedical platforms, 78–79, 81–83
 - disjointedness of, 85
 - LMICs and, 88
 - Stempeutics and, 83, 87
 - technological rationale of, 89
- biomedical products
 - clinical research and, 40
 - human rights–based discourse and, 204
- BioNexus-status companies, 56
- Biostar Research Institute, 234
- Biosystems, 167
- biotechnology, 185, 266–268
 - well regulated forms of, 113
- Black, Julia, 4, 7, 215
- bona fide science practices, 42, 63
- bone marrow-derived mesenchymal stem cells (BM-MSC), 70
 - FDA and, 104
 - GvHD and, 74
 - thalassemia and, 136
- boundary-making. *See* regulatory boundary-making
- boundary-work. *See* regulatory boundary-work
- bowel- and bladder-management, 187, 194
- Braithwaite, John, 5, 35
- Brazil, 42
- Breakthrough Therapy Designation, 51, 114
- Brexit, 238
- Brian Salter, 258
- bribery, 111
- brokerage. *See* regulatory brokerage
- Bufacchi, Vittorio, 8
- bureaucracy, 9, 97
 - free individuals and, 205
 - Japan and, 156
 - Japanese–Thai collaboration and, 130
 - rogue science and, 111
- Busch, Lawrence, 34
- Bush, George W., 41, 152
- California Institute for Regenerative Medicine (CIRM), 232
- Calvert, M. J., 213
- Cambodia, 131
- Cambrosio, Alberto, 82
- Canada, 81
- capacity building. *See* regulatory capacity building
- capital. *See* regulatory capital
- capitalism. *See* regulatory capitalism

- Caplan, Arnold, 104
 caring solidarity, 19, 23, 26–27, 269–271
 competition and, 246
 competitive desire and, 31, 241
 regulatory brokerage and, 212, 214
 regulatory concepts and, 212
 Cartistem, 58, 233
 case studies, 18–19
 Castells, Manuel, 35
 catching-up policies, 66
 category-3 drugs, 68, 70
 caution, 267
 Celgene, 249
 Celixir, 238
 cell and gene therapies (CGTs), 227
 Cell and Gene Therapy Catapult, 226
 cell banks, 249
 biobank initiatives and, 60
 HLA and, 12
 standards for, 175
 See also umbilical cord blood banks (UCB)
 cell ossification, 130
 cell processing, 173
 smart form of, 229
 Cell Products & National Engineering Research Center, 71–72
 cell reprogramming, 11–12, 156–157, 172
 cell sourcing, 11, 171
 politics of, 178
 Cell Surgical Network (CSN), 115
 cell therapy products (CTPs), 174–175
 advertised as cell treatment, 53
 Taiwan and, 236
 CellSeed, 222
 cell-sheet therapy, 221–222
 Heartsheet and, 225
 Cellular Biomedicine Group Inc. (CBMG), 62
 Central Drugs Standard Control Organisation (CDSCO), 80
 Central Military Commission (China), 72
 central planning, 34
 Centre for Biosystems Dynamics Research, 177
 Centre for Cells and Tissue Engineering, 74
 Centre for iPS Cell Research and Application (CiRA), 163–167, 169–170, 174–175, 178–179
 AJS led by, 169, 171–172, 177
 branding for, 168
 changes to protocols and, 168
 criticisms of, 176
 Kyoto University and, 133
 pilot study by, 172–173
 pressure to work with, 173
 Takahashi and, 171
 Yamanaka and, 157, 160–162
 charities, 188
 HOs and, 203
 Doctor Chaturvedi (pseudonym), 83
 Chen, Y.-C., 236
 China, 55, 111–112
 2009 regulations and, 108–109, 112
 2015 draft regulation and, 73, 75
 2015 regulation and, 77
 AJS and, 164
 Beike Biotech and, 29, 108–112
 CAMS and, 70–71
 elite laboratories and, 88
 entry into global science-competition and, 42
 forms of authority in, 48
 Guangzhou Alliance and, 74–75
 Guangzhou use of local authority in, 49
 hegemonic approaches and, 66, 69
 HOs and, 205
 industry collaboration and, 197–198
 international networks and, 60–62
 Japan and, 237–238
 Japanese–Thai collaboration and, 138
 knowledge activism and, 202–203
 LMIC collaboration and, 57
 lobbying in, 190
 military research and, 72–73
 MSC safety and, 104
 needs of disabled and, 190–191
 NGOs and, 188
 off-label use in, 49
 regulatory boundary-work and, 64
 regulatory brokerage and, 215

- regulatory capacity building and, 67–69
- regulatory immunity and, 92, 240
- regulatory orientation and, 69–71, 75–78
- regulatory reputation and, 102
- SCI and, 194–195, 200
- semi-private enterprises and, 75–76
- shared scientific cultures and, 52
- stem cell trials in, 13
- Tianjin stem cell cluster and, 71–72
- UK and, 101
- universal regulation and, 107, 122
- US unauthorised clinics and, 115
- China Bone Marrow bank, 72
- China Disabled Persons Federation (CDPF), 189
- China Food and Drug Administration (CFDA), 68
 - Administrative Measures of Clinical Research for Stem Cells (for Trial Implementation) (CFDA 2015), 68, 237–238, 282
 - Beike and, 109
 - BM-MSCs and, 70
 - Guangzhou Alliance and, 75
- China SCI-Net, 61
- China-bashing, 111
- Chinese Academy of Medical Sciences (CAMS), 70–71
 - collaboration with, 76
 - military research and, 73
 - Peking Union Medical College and, 71
- Chinese Academy of Sciences (CAS), 73
- Chinese Medicine Registry and Management System, 69
- chongsaem law ('cutting-edge regenerative' law), 233
- Choose Wisely, 266
- chronic and life-limiting illnesses, 254
- Chulalongkorn University (CU), 29, 124–125, 139, 219–221
- Cipla, 82–83
- CITIC (China International Trust and Investment Corporation), 75
- Class 1 treatments, 224
- clinical firsts, 250
- clinical research, 121
 - biomedical products and, 40
 - Japan and, 159
 - national vs. local permission for, 49
 - vindication of, 152
- Clinical Research Organisations (CROs), 261
- clinical research trials (CRTs), 2
 - AJS and, 154–155, 173
 - biotech industry and, 88
 - clinical, 14
 - clinical research and, 166
 - cost-benefit analysis of, 254–256
 - high expectations of participation in, 255
 - Indian bureaucracy and, 52
 - onus of risk and, 22
 - pathways for, 169–171
 - patient populations and, 260–263
 - PMDA and, 158
 - RCTs and, 53–55
 - regulatory challenges and, 16–18
 - regulatory threshold for, 157
 - research therapy tension and, 15
 - safety and efficacy studies of, 165
 - social contract and, 257–258
 - state investment and, 252
 - stem cell therapies and, 12
 - tension between therapy and, 14–15
 - See also* randomised control trials (RCTs)
- ClinicalTrials.gov, 12, 109, 115
- Coca-Cola, 197
- collaboration, 1, 3, 18, 124–126
 - AJS and, 163–165, 168, 177–179
 - alternative therapeutic practices and, 63
 - anything goes attitude and, 65
 - case studies of, 19
 - China and, 76
 - CiRA and, 174
 - company competition and, 172
 - competition and, 29, 64, 123
 - competitive desire and, 213
 - Guangzhou Alliance and, 74–75
 - health organisations and, 189, 196–198
 - increase in regulatory competition and, 42

- collaboration (cont.)
 - industry and, 175
 - Japanese universities and, 159
 - Japan–Thailand and, 131–133, 140–145
 - local authority and, 49
 - loose regulation and, 56
 - networks for, 44
 - niches for, 124
 - R-CPX and, 127–128
 - regenerative therapy and, 176–177
 - regulatory brokerage and, 64, 209
 - regulatory capital and, 145–147
 - regulatory discrepancies and, 130–131
 - regulatory immunity and, 239
 - regulatory knowledge and, 22
 - regulatory manipulation and, 35
 - regulatory orientation and, 77–78
 - regulatory patterns in, 244
 - regulatory redemption and, 150–151
 - scientific results of, 133–135
 - trust and, 137–139
- commodification, 263
- common good, 265–266
- communal norms, 96
- community, 187–188, 204, 263–265
 - common good and, 265
 - SCI and, 182
- commutative justice, 268
- compassionate treatment, 50, 223
- competition, 2, 17
 - Australia and, 117
 - biological notions of, 213
 - clinical firsts and, 210
 - collaboration and, 29, 64, 123, 146
 - company affiliation as cause of, 172
 - destructive forms of, 216
 - international dynamics of, 62
 - Japan and, 233–234
 - mimetic rivalry and, 93–94
 - regulatory brokerage and, 209
 - regulatory capacity-building and, 88
 - regulatory capital and, 125
 - regulatory capture and, 40
 - regulatory reform and, 231
 - regulatory violence and, 3
 - structural spaces for, 100
 - UK and, 101
 - unreliability and, 37
- See also* competitive desire; regulatory capitalism; regulatory violence
- competitive desire, 23–24, 26–27, 30
 - caring solidarity and, 31, 241, 269–271
 - collaboration and, 124–126
 - common good and, 265
 - Cossu and, 253
 - cost-benefit analysis and, 248
 - costs of, 253
 - foreseeable harm and, 238, 243
 - Girard and, 93
 - governance and, 250–251
 - Japan's 2013 reforms and, 30
 - legal justice and, 269
 - mimesis and, 263–264
 - mimetic rivalry and, 97
 - regulatory brokerage and, 209, 211–214
 - regulatory reform and, 240
 - scapegoating and, 29
 - scientific value and, 252
 - social contract and, 246, 256, 258
 - state investment and, 45
 - virtue ethics and, 269
- compliance, 5, 44, 55
- Comprehensive Special Zones, 225–226
- conditional approval, 230
 - AJS and, 180
 - India and, 235
 - REGROW Bill and, 241
 - Stempeucel and, 235
 - Taiwan and, 236
 - time-conditions and, 224, 229–230, 236
 - US and, 254
- conflict avoidance, 146
- conflict, collaborative contexts for, 126
- contract development and
 - manufacturing companies (CDMOs), 249
- contract research organisations (CROs), 73
- Control and Supervision of Drugs and Products from Stems Cells amendment (Thailand), 131

- corneal cells, 218
- cosmetic therapy, 53, 80, 84–85, 89
 - Japanese–Thai collaboration and, 131
 - reputational effects of, 21
- Cossu, Giulio, 243, 253–254, 256–258
- cost-benefits analysis, 254–256
 - community action and, 267
 - competitive desire and, 248–249
 - regulatory violence and, 248
 - virtue ethics and, 269
- cost-effectiveness of treatment, 254
- COVID-19, 214
- creative desire, 27, 32
 - caring solidarity and, 212, 263–265, 270
 - generative principle of, 246
 - mimesis and, 212
 - regulatory concepts and, 211
- creative mimesis, 263–264
- Critical Limb Ischemia, 87
- critical theory, 181
- Crohn's disease, 58, 254–255
- Croley, Steven, 6
- cryopreservation, 84
- Cupistem, 58, 233
- Custom Market Insight (CMI 2023), 249
- Cyranoski, D., 179
- cytokine production capacity, 84
- Cytori Therapeutics, 59, 84

- Dallas Buyer's Club* (film), 181
- Dana and Christopher Reeves Act, 200
- Deane-Drummond, Celia, 266–268, 270
- Deinsberger, Julia, 12
- Deloitte, 238
- democratic decision-making, 94, 258
- Demouchel, Paul, 126, 259
- Department of Biotechnology (DBT) (India), 80, 86, 218
 - ISSCR criticism and, 235
- Department of New Energy and Industrial Technology Development Organization (NEDO), 125, 132, 137, 219–220
 - regulatory capital and, 145
 - regulatory tolerance and, 147
- deregulation, 4, 30, 113
 - as form of brokerage, 217
 - FTCM and, 183, 231
 - international brokerage and, 226
 - international health organisations and, 241
 - international patient movements and, 154
 - Japan and, 224–225, 229
 - neoliberalism and, 36
 - regulatory capital and, 146
- desire, 243
 - forms of, 269–271
- destructive desire, 243
- developmental pathways, 81–83
 - length of, 227
 - regulatory orientation and, 78–79
 - therapy provision and, 80
- dialectic of co-production, 150–151, 155, 163
- dialectic of regulatory reproduction, 151
- Diet (parliament of Japan), 222
- difference. *See* regulatory difference
- diplomatic immunity, 92
- direct-to-consumer provision (DTCs), 107, 122
 - Australia and, 117
 - caring solidarity and, 241
 - Japanese–Thai collaboration and, 130
- disability, 190–193
 - China classifications of, 189
 - self-perception of, 187
 - societal roots of, 184
- discrepancy. *See* regulatory discrepancies
- disease conditions, 254
- distributive justice, 268
- diversity, 206
- donation vs. leasing, 132, 136, 138–139, 145
- down-regulation, 162, 181, 184, 186, 223
 - misrecognition and, 153
 - patient movements and, 30
 - regulatory redemption and, 30, 154, 205

- Drug Administration Law (China, 2001), 67
- Drug Controller General (India), 80
- Drugs and Cosmetics Act (1940), 235
- Drugs and Cosmetics Act (DCA), 80
- Drugs Controller General, 87
- dual-track systems, 236–237
- Duchenne muscular dystrophy (DMD), 50, 193
 - cost-effectiveness and, 254
 - personal decision-making and, 255
- Dupuy, Jean-Paul, 271
- Early Access to Medicine Scheme, 51
- early-access programs, 238
- ‘The East or Scientific Feast’ (Anonymous, *Economist Magazine*), 41
- Eastern Europe, 183
- economic growth, 13, 26, 59, 64, 246
 - Australia and, 117
 - competitive desire and, 250
 - LMICs and, 121
 - regulatory brokerage and, 209
 - regulatory violence and, 248
 - targets for, 66, 88
- economic metaphors, 92
- elites, 25, 43–44, 67, 93
 - CAMS proactive orientation and, 71
 - funding and, 69
 - importing regulation by, 81
 - Japanese–Thai collaboration and, 147
 - network criticism by, 72
 - regulation and, 40
 - regulatory boundary-work and, 88
- embodied conditions, 31
- embodied ideals, 153
- embodied identities, 103, 184, 203–204
- embryo sourcing, 11
- empathy, 27
- enablement, 113, 123
- endogenous stem cell therapy, 11
- Entrepreneurial life-science networks, 44
- entrepreneurial networking, 82
- entrepreneurialism, 117, 183, 207, 210–212
 - innovation and, 52
 - prohibitive regulation and, 239
 - regulatory brokerage and, 216
 - regulatory gaps and, 206
 - science management and, 31
 - Tianjin cluster of, 71
 - unauthorised therapies and, 115
- Esposito, Robert, 95
- ethics, 16–18
 - acceptable science and, 44, 94
 - Beike patients and, 111–112
 - caring solidarity and, 271
 - ethics, 23
 - hegemony and, 69
 - local considerations and, 151
 - markets and, 96
 - practice of, 76
 - rational individualism and, 263
 - recklessness and, 102
 - regulatory immune-tolerance and, 95
 - scientific integrity and, 101
 - scientific uncertainty and, 99
 - socio-political positions and, 152
 - toeing the regulatory line and, 76
 - unethical binary with, 123
 - universal application of, 106
 - universal appraisals of, 105, 107
- ethics of return, 56
- ethnocentrism, 204
- Europe, 227–228
 - Beike image in, 109
 - blood donation in, 173
 - compassionate treatment and, 223
 - FDA and, 151
 - international patient movements and, 154
 - knowledge activism and, 202
 - lay-expert input and, 197
 - modernity and, 113
 - patient movements and, 183
 - patient populations and, 261
 - private interest theories in, 6
 - registries in, 201
 - soft law and, 48
 - trust in state regulators in, 205
 - UK and, 251
 - unauthorised clinics in, 22
 - US and, 232

- European Bank for iPSCs (EBiSC), 60
- European human Pluripotent Stem Cell Register (hPSCreg), 60
- European Medicines Agency (EMA), 48, 51, 100, 118–120
 - Biologics and, 116
 - direct-to-consumer and, 122
 - Orphan Drug Designation and, 51
 - regulatory capital and, 145
 - regulatory immunisation and, 121
 - WHO and, 123
- European Union (EU), 118–120
 - 2007 Regulation and, 100
 - accelerated approval and, 51
 - compassionate treatment and, 50
 - Hospital Exemption clause in, 116
 - influence of reform and, 231
 - Japanese reform and, 232
 - Japan–Thailand collaboration and, 128
 - market acceleration and, 51–52
 - patient protection in, 100
 - piecemeal regulation and, 59
 - RCTs and, 53–55
 - regulatory boundary-work and, 64
 - regulatory dynamics of, 63
 - regulatory exemptions and, 22
 - regulatory overhaul and, 42
 - regulatory tolerance and, 121
 - standards set by, 67
- European Union Tissue and Cells Directive, 118
- Eurostemcell (2022), 60
- evidence-based medicine, 15
- exemptions, 116
 - acceleration and, 205
 - Australia and, 117
 - HICs and, 121
 - US and, 115
- expanded access, 114–115
 - related mechanisms for, 223
- experimental practices, 16–18, 63
 - Australia and, 116–117
 - Beike and, 111
 - collaborative scientific results and, 133
 - HOs and, 205
 - political desire and, 105
 - protection of human subjects in, 14
 - regulatory exemptions for, 50–51
 - regulatory immunity and, 94
 - Wharton's jelly cells as, 120
- experimentation. *See also* innovation
- exploitation, 93, 95
- exploited regulatory brokerage, 26
- family banking, 72
- family care, 192
 - RCTs as alternative to, 106
- FBRI (Foundation for Biomedical Research and Innovation), 164, 167, 176
- FDA Safety Innovations Act (FDASIA), 51
- French-Constant, Charles, 120
- fieldwork, 19–20
- Five-year Healthcare Innovation Strategy, 222
- Five-year Medical Innovation Programme, 160
- flexibility. *See* regulatory flexibility
- Foong, Patrick, 117
- Fordist production management, 35
- foreignness, 24
 - clinical trials and, 205
 - experimental medicine and, 106
 - regulation and, 25, 28
 - scapegoating and, 96
 - See also* rogue practices
- foreseeable harm, 1–3
 - caring solidarity and, 269
 - competitive desire and, 243
 - definitions of violence and, 8–9
 - mimetic cultures and, 244
 - politics and, 29
 - regulatory brokerage and, 209–212, 215, 238
 - regulatory violence and, 247
 - table of concepts including, 211
 - See also* regulatory violence; violence
- foresight, 267
- Forum for Innovative Regenerative Medicine (FIRM), 175, 221–222
 - companies within, 226
 - global brokerage and, 229–230
 - US influence and, 232

- Foundation for Biomedical Research
 and Innovation (FBRI), 166
 four-phased trials, 14, 16, 53–55
 France, 251
 soft law and, 48
 fraudulent science, 42
 Free to Choose Medicine (FTCM), 181,
 206, 231–232
 deregulation and, 154
 EU and, 120
 HOs and, 183–184
 lobbying and, 190
 freedom of choice, 200
 fresh-cell therapy, 118
 Friedman, Milton, 34, 36
 Fukuoka Trinity Clinic, 234
 funding, 156–159
 AJS and, 175, 177
 Bush moratorium on, 152
 CiRA and, 174
 developmental pathway length and,
 227
 elite laboratories and, 69
 HOs and, 189
 hybrid forms of, 71
 Japan and, 223
 redirection of, 256
 virtue ethics and, 269

 G-10 group, 36
 GATT rules, 144
 GEN website, 249
 General Agreement on Trade in
 Services (GATS), 36
 genetic testing, 187
 genome analysis, 166
 Germany, 118
 Gieryn, Thomas, 37, 42
 gift economies, 259–260
 gift-giving, 263–264
 Girard, Rene, 26, 31, 93, 213
 imitative desire and, 264
 mimetic rivalry and, 100
 global hegemony approach, 66
 Global North, 184
 Global Regenerative Medicine Market
 Report – 2019 (GRMMR), 249
 Global South, 184

 globalisation, 29, 100
 caring solidarity and, 270
 collaboration and, 124
 competition and, 28
 hegemonic approaches to, 65–66
 illegitimate regulatory brokerage
 and, 244
 nation-states and, 246–248
 neoliberalism and, 33–36
 patient populations and, 261
 pioneering industries and, 89
 regulatory brokerage and, 228–231
 regulatory discrepancies and, 242
 regulatory gaps and, 239
 social contract and, 259–260
 variability and, 44
 See also international regulation
 Dr Gong, 110
 Good Clinical Practice (GCP), 55, 237
 Good Gene, Cell and Tissue Practice
 (GCTP), 169, 171
 Good Laboratory Practice (GLP), 36, 49
 India and, 235
 Japan–Thailand collaboration and,
 127–128
 PMD pathway and, 169
 scarcity of resources and, 39
 Thailand and, 141–142
 Good Manufacturing Practice (GMP),
 36, 49, 55, 107
 collaborative science and, 133
 India and, 235
 industrial standards and, 176
 non-homologous use and, 113
 PMD pathway and, 169
 R-CPX and, 130, 135
 RM Act and, 173
 scarcity of resources and, 39
 state investment and, 251
 Thailand and, 141–142
 good practice requirements, 55
 governance, 208
 AJS and, 159–163
 competitive desire in, 250–251
 HOs and, 186–190
 knowledge activism and, 199–201,
 203
 See also politics

- Graft versus Host Disease (GvHD), 50, 70, 74–75
 controversial applications of, 105
 R-CPX and, 137
 Temcell and, 225
 grass-root organisations, 188. *See also* patient organisations
 grey experimental industries, 117
 GTP (good tissue practice), 55
 Guangzhou Alliance, 74–75
 Guangzhou City Large S&T Expert Program, 74
 Guangzhou Huanhuang, 75
 Guangzhou Hygiene Department, 75
 Guangzhou Institute for Biomedicine and Health (GIBH), 74
 Guangzhou Province, 49, 61
 Guangzhou Stem Cell and Regenerative Medicine Alliance, 61
 Guidance for Research and Evaluation of Cellular Therapy Products (China), 237
 Guidelines for Stem Cell Research and Therapy (India), 80–81
- Haelios, 171
 Han, Zhongchao, 71–72
 Hanshi, 75
 Hanshi (Beijing Health and Biotech Group), 72
 Haraway, Donna, 92
 hard law, 48, 52, 58
 harmonisation. *See* regulatory harmonisation
 Hashigawa (from FBRI), 176, 223
 Hayek, Friedrich, 34
 Headquarters of Healthcare Policy (Japan), 158
 Healios, 166, 177
 Health and Pharmaceutical Promotion Strategy, 155, 160, 164
 health organisations (HOs), 185–186
 cost-effectiveness and, 254
 deregulation and, 241
 diverse needs of disabled and, 190–193
 down-regulation and, 254
 health activism and, 203–204
 industry and, 196–198, 253
 internationalisation of, 181–184
 knowledge activism, 199–203
 locally situated demands and, 193–196
 patient wishes and, 184
 personal decision-making and, 255
 political governance and, 186–190
 political identity and, 204–206
See also networks; organisational levels; patient organisations
 Healthcare Engineering Group, 129
 healthcare insurance, 159, 224, 253
 Beike and, 111
 biotechnology ethics and, 267
 cost-benefit analysis and, 255
 globalisation and, 260
 industry seeking payouts from, 197
 national schemes for, 106
 universal coverage and, 136–137
 Heartcellgram, 58, 233
 Heartland Institute, 183, 231
 Heartsheet, 225
 hegemony, 63
 approaches to, 65–66
 down-regulation and, 184
 ethical conformity and, 69
 health activism counter to, 204
 LMICs and, 88
 patient movements and, 182
 regulatory capacity building and, 89
 regulatory redemption and, 150
 hematopoietic stem cells (HSCs), 10–11
 Thailand and, 140
 Zhao research on, 70
 heterogeneous cell lines, 12
 high-income countries (HICs), 3, 121–122
 biotechnological solutions and, 185
 biotechnology ethics and, 267
 bureaucracy and, 205
 caring solidarity and, 264
 collaboration and, 124
 Cossu and, 253
 cost and, 254
 counter-hegemony and, 204
 enablement and, 123
 experimental practices and, 63

- high-income countries (HICs) (cont.)
 hegemony theories and, 66
 HOs and, 186, 189
 industry collaboration and, 196–198
 knowledge activism and, 199–203
 MD and, 195
 MSCs and, 99
 needs of disabled and, 191
 political lobbying in, 190
 regulatory brokerage and, 209
 regulatory gaps and, 206
 regulatory tolerance and, 112
 SCI and, 193, 195
 sustainability of healthcare in, 21
 view of fraudulent science in, 42
 ‘Highway to the Realization of
 Regenerative Medicine’ (Japan),
 157
 HLA (human leukocyte antigen)
 matching, 11–12
 holistic medicine, 53
 home-keeping strategy (Japan), 230
 homologous use, 113
 Hong Kong University of Science and
 Technology, 109
 horizontal pressure, 215
 Hoshino, Toshihiko, 160, 162
 Hospital Exemption (HE) (EU), 50,
 116, 119–120, 223
 Article 5(1), 50
 non-routine use and, 53
 House of Lords (UK), 238
 debate in, 251–252
 Huaxia Ganxibao Lianmeng (Beijing
 Health and Biotech Group), 72
 human embryonic stem cell research
 (hESC), 175–176
 Bush 2001 moratorium on, 41
 hESC moratorium and, 41
 investment in, 13
 IPS cells and, 156
 Japan and, 157
 upscaling production of, 249
 US funding cuts and, 101
 human-rights discourse, 184
 Hunan Guangxiu Biological Science
 Co., Ltd., 76
 Hunan Guangxiu Hospital, 76
 Hunan Provincial government, 76
 Hwang Woo-Suk, 41, 194, 196, 198
 Hybrid Assistive Limb (HAL®), 194
 ideal regulation, 78
 inequality and, 146
 identity, 184
 care and, 268
 discursive messaging and, 96
 normalcy and, 256
 imitation, 26, 100
 caring solidarity and, 270
 Girard and, 213
 imitative desire, 93, 97
 objectification of others and, 264
 immature therapies, 16
 immune reactions, 12
 immune suppressants, 176
 immune tolerance. *See* regulatory
 immune tolerance
 immunitarian force, 93–94
 immunitary politics, 125
 regulatory capital and, 148
 immunitas, 93–97
 immunological rejection, 170
in vitro generation, 13
 India, 52, 55
 2007 stem cell guidelines and, 86
 2013 regulation and, 235
 bureaucracy in, 52
 elite laboratories and, 88
 globally shared patient needs and,
 204
 Guidelines for Stem Cell Research
 and Therapy in, 80–81
 hegemonic approaches and, 66
 HO recognition in, 190
 HO registries and, 201
 HOs and, 205
 human rights discourse and, 203
 industry collaboration and, 197
 international guidelines and, 67
 Japan and, 234–236
 Japanese–Thai collaboration and,
 138
 kosher/rogue binary in, 103
 LMIC collaboration and, 56
 needs of disabled and, 190–192

- NGOs and, 188
- off-label use in, 49
- phase three trials and, 181
- regulatory boundary-work and, 64
- regulatory immunity and, 92, 240
- responsible innovation in, 78–79
- SCI and, 194, 200
- stem cell tourism and, 195
- Stempeutics and, 83–84
- Stempeutics model and, 85–87
- UK and, 101
- ZCRM and, 218–219
- Indian Council of Medical Research (ICMR), 52, 80–81, 86, 218
- Indian Institute of Science (IISc), 82
- indirect violence, 7–8
- individual responsibility, 248
- individual-rights discourses, 202–203
 - health activism and, 204
- induced pluripotent stem cells (iPSCs), 10–12
 - AJS and, 155, 160–162, 174–179
 - AMD and, 163
 - assays for, 167–169
 - CiRA and, 163–166, 171–173
 - clinical trial pathways for, 169–171
 - collaborative science and, 133
 - competitive desire and, 250
 - creation of, 156–157
 - discovery of, 41
 - GMP conditions and, 173
 - investment in, 13
 - Japanese regulation of, 58
 - politics of, 156
 - publication and, 134
 - regenerative therapy and, 165
 - research success and, 158–159
 - state investment and, 249–250
 - Yamanaka Nobel Prize and, 136
- industry, 171
 - AJS and, 175–176
 - Australia and, 117
 - HO collaborations with, 189
 - HOs and, 196–198, 253
 - individual-rights discourses and, 203
 - investment and, 88
 - Japanese investment and, 223–224
 - Japanese–Thai collaboration and, 142
 - regulatory gaps and, 206
 - responsible image of, 86
 - state investment and, 252–253
- inequality, 146–147
 - political movements and, 154
- infections, 176
- infrastructure, 261, 269
 - effective creation of, 77
- Japan and, 158
- Initiatives under the Project for Japan
 - Translational and Clinical Research Core Centers policies (Japan), 158
- innovation, 4
 - contested science and, 105
 - exemptions for, 50
 - market acceleration and, 51–52
 - regulatory orientation and, 88
 - responsibility and, 78–79, 81, 86
 - See also* experimentation
- Institute for Biomedical Research and Innovation (IBRI), 167
- Institute of Hematology (PUMC), 71–72
- Institutional Committee for Stem Cell Research (IC-SCR), 80, 235
- Institutional Ethics Committee (IEC) (India), 80
 - guidelines from, 219
- institutional review boards (IRBs), 16, 49
 - Guangzhou Alliance and, 75
 - Thailand and, 140–141
- Integrated Cell-Material Sciences (iCeMS), 164
- intellectual property rights (IPR), 43–44
 - Beike and, 110
- intentionality, 8
- interest groups, 215
- interest-group theory, 6
- ‘Interim Regulations on the Ethical Review of Biomedical Research Involving Human Subjects’ (MoH 2007), 67
- internal mirroring, 92–93
- International Alliance for Biological Standardization (IABS), 176

- International Association of Neurorestoratology (IANR), 61, 97
- International Cellular Medicine Society (ICMS), 60
 - credible authority and, 97
- International Clinical Trials Registry Platform (ICTRP), 12
- International Consortium of Stem Cell Networks (ICSCN), 60
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), 229
- International Monetary Fund (IMF), 36
- International Organization for Muscular Dystrophy (IOMD), 182
- International Organization for Spinal Cord Injury (IOSCI), 182
- International Pharmaceutical Regulatory Harmonization Strategy, 230
- international regulation, 5, 24
 - 2008–2014 period for, 62
 - China's adaptation of, 112
 - Chinese state laboratories and, 111
 - collaboration and, 124
 - competition and, 2, 34
 - credible authorities for, 97
 - global competition and, 27
 - global dynamics of, 18–19
 - guidelines and, 55
 - health organisation standards and, 205
 - hegemony and, 88
 - HOs and, 181–184
 - international, 47
 - knowledge of, 22
 - participation in, 45
 - patient movements and, 30
 - regulatory boundary-work and, 60–62
 - regulatory brokerage and, 239
 - regulatory capital and, 145–146
 - unauthorised clinics and, 108
 - See also* globalisation
- International Society for Cellular Therapy (ISCT), 60, 67
 - formulation of regulations and, 45
 - Japanese–Thai collaboration and, 134
 - social contract and, 260
- International Society for Stem Cell Research (ISSCR), 60, 62, 67, 229
 - China and, 237
 - credible authority and, 80
 - formulation of regulations and, 45
 - India criticised by, 235
 - Japan and, 151
 - Japanese–Thai collaboration and, 134
 - regulatory capital and, 145
 - scarcity of resources and, 39
 - social contract and, 260
- International Society of Plastic Surgeons, 85
- International Stem Cell Bank Initiative (ISCBI), 60, 167
 - defining pluripotency and, 174
 - industrial standards and, 176
- International Stem Cell Forum (ISCF), 60
- International Stem Cell Initiative (ISCI), 43, 60
- International Stem Cell Registry (ISCR), 60
- inverse care law, 256
- investigational new drugs (INDs), 49, 115
 - CiRA and, 173
 - Japan and, 223
 - US and, 115
- investigational use, 80
 - FTCM and, 183
- investment, 88, 171
 - caring solidarity and, 269–270
 - Japanese industry and, 223–224
 - political desirability and, 104
 - state support for, 249–250
 - virtue ethics and, 269
- in-vitro fertilisation (IVF), 75–76
- Invitrogen (ABI), 167
- Invossa, 233
- ischemic stroke trials, 73
- Italy, 119, 197
 - AIFA medical agency and, 120
 - regulatory tolerance and, 121
- Japan, 124–127
 - Australia and, 117
 - caring solidarity and, 241

- China and, 237
- competitive desire and, 250
- competitive reform and, 233–234
- conditional approval and, 231
- fast-track pathways and, 57–60
- forms of brokerage and, 217
- FTCM and, 231
- funding overhaul in, 156–159
- global brokerage and, 229–231
- HOs and, 194–195, 205
- India and, 234–236
- industry collaboration and, 198
- informal brokerage and, 219
- informal regulatory brokerage and, 218
- international brokerage and, 224–228
- knowledge activism and, 202
- LMIC collaboration and, 56
- market acceleration and, 51
- national insurance and, 253
- other country experiences similar to, 253
- patient financial contributions in, 106
- reform and, 30, 127
- regulatory boundary-work and, 64
- regulatory brokerage and, 239
- regulatory capacity building and, 217
- regulatory dynamics of, 63
- regulatory immunity and, 240
- regulatory overhaul and, 42
- SCI and, 201
- shared scientific cultures and, 53
- social contract and, 258
- soft law and, 48
- South Korea and, 232
- state investment and, 250, 252
- state support brokerage and, 219–221
- stem cell trials in, 13
- Taiwan and, 236–237
- tax on legacies in, 188
- UK and, 238, 252
- See also* All Japan System (AJS)
- Japan Medical Association, 165
- Japan Muscular Dystrophy Association (JMDA), 195
- Japan Revitalization Strategy, 219
- Japan Science and Technology Agency (JST), 163–165
- Japanese Society of Regenerative Medicine (JSRM), 221–222, 234
- Japanese–Thai collaboration, 124–127, 131–133, 143–145
- R-CPX and, 133–135
- regulatory capital and, 145–147
- regulatory discrepancies and, 130–131
- state support brokerage and, 219–221
- Jerne, Niels, 92
- Jiao Hong, 215
- Jordana, Jacint, 5, 35
- judgement, 267. *See also* community judicial systems, 94
- June, 249
- justice, 27, 32, 214, 265–266, 268–269
 - caring solidarity and, 212, 270
 - common good and, 265–266
 - creative desire and, 263
 - local notions of wisdom and, 246
 - patient protection and, 15
 - sacrificable victims and, 259
 - See also* caring solidarity
- Kanagawa Centre for Clinical Research and Strategy, 226
- Kanishka (pseudonym), 82
- Kawa (researcher at iCeMS), 163–164
- Kawasaki (Japan), 226
- Kawasaki Heavy Industry (KHI), 29, 124–129, 143–144
 - collaborative scientific results and, 133–135
 - Japanese–Thai collaboration and, 131–132
 - medical use and, 136–137
 - regulation and, 140–143
 - regulatory capital and, 145, 147
 - state support brokerage and, 219–221
 - trust and, 138–139
- Keating, Peter, 82
- Keihin Coastal Areas Comprehensive Special Zone for International Competitiveness, 225–226

- Keio University, 160
- KenCare, 57
- Keynesianism, 34
- Kishi (scientist), 172–173
- knowledge activism, 190, 196, 199–203
- knowledge assets, 14, 132, 134, 178
- Kolon TissueGene, 233
- Korean Food and Drug Administration (KFDA), 57, 232–233
- Korean Ministry of Food and Drug Safety (MFDS), 58
- kosher practices, 29, 103
 - discursive identification and, 97
 - foreign practices and, 24
 - grey areas and, 95
 - regulatory immunity and, 93
- K-Stemcell, 57
- Kuala Lumpur (Malaysia), 87
- Kumar, M. (pseudonym), 82–85, 218
- kusakariba ‘cutting from the hay-meadow commons’, 225
- Kyoto University, 160
 - Centre for iPS Cell Research and Application (CiRA), 133
 - off the shelf cells and, 171
- Kyoto University Hospital (KUH), 170
- RM Act and, 173
- Kyoto University Medical School, 164
- Lancet Report (Cossu et al.), 243
- Lanphier, Edward, 230
- ‘Large-scale cell production of stem cells for clinical application using the automated cell-processing machine’ (Kami et al. 2013), 133
- last resort treatment, 75
- Latin America, 182
- Latour, Bruno, 113
- law, 95
 - establishment of, 93–94
 - rule of, 15, 36
 - transcendental power and, 96
- legal justice, 268
- Levi-Faur, David, 5
 - regulatory state approach and, 5
- liberalism, 34
- Life Innovation Centre (LIC), 226
- Life Technology, 167
- Lifecell, 61
- Lippmann, Walter, 34
- lobbying, 35, 188, 190
 - active brokerage and, 239
 - FTCM and, 190
 - health funding priorities and, 45
- localities, 44, 63
 - caring solidarity and, 270
 - collaboration and, 49
 - creative desire and, 264
 - dilemmas of, 66
 - disability and, 190–193
 - Guangzhou Alliance and, 75
 - hegemony and, 89
 - ideal regulation and, 78, 105–107
 - international networks and, 60–62
 - international regulation and, 67
 - jurisdictional differences and, 23
 - knowledge activism and, 201
 - LMICs and, 56, 122
 - local practices, 31
 - locally situated demands and, 193–196
 - organisational networks and, 216
 - patient populations and, 261–262
 - prudence and, 265
 - regulation in, 20, 63
 - regulatory boundary-work and, 46
 - regulatory brokerage and, 243
 - regulatory capacity building and, 77–78, 211
 - regulatory contagion and, 147
 - regulatory orientation and, 69, 77
 - regulatory redemption and, 149–154
 - rogue experimentation and, 103
 - self-help solutions and, 267
 - shared scientific culture and, 52
 - therapy provision and, 27
 - wisdom and, 246, 263, 268
 - workspaces and, 188
- loopholes, 116
- loose regulation, 56
- loving desire, 263
- lower and middle-income countries (LMICs), 1
 - Beike Biotech case and, 108, 111
 - biotechnology ethics and, 266–267
 - collaboration and, 124
 - Cossu and, 253

- economic growth in, 121
- hegemony and, 65–66, 89
- HOs and, 186, 193–194, 204–206
- industry collaboration and, 198
- international guidelines and, 67
- investment by, 14
- knowledge activism and, 199–200, 202–203
- local communities and, 263–265
- MSCs and, 99
- needs of disabled and, 192
- neoliberalism and, 64
- network complexity and, 70
- patient financial contributions and, 106
- patient movements and, 182
- regulatory boundary-work and, 59, 88–89
- regulatory dynamics of, 63
- regulatory immunity and, 105
- regulatory redemption and, 25
- SCI and, 195
- scientific ambitiousness and, 55
- shared scientific cultures and, 52
- small country investment and, 56–57
- sustainability of healthcare in, 21
- universal regulation and, 122
- Western hegemony and, 41
- Lu Daopei hospitals, 77
- Lu Guangxiu, 75–76
- Magellan Stem Cells, 116
- Majone, Giandomenico, 5–6
- major histocompatibility complex (MHC)–matched iPSCs, 170
- Malaysia, 56–57, 64
 - Stempeutics branch in, 81–82, 85, 87
- Malaysian Biotech Corporation, 56
- malpractice, 80
- Management Measures for the Clinical Use of Medical Technologies (MoH), 68
- Management of Clinical Research and Transformation Applications for Somatic Cell Therapy (China), 237
- ‘Manifesto for Slow Science’ (Stengers), 214
- Manipal Education and Medical Group (MEMG), 81–83
- Manipal Hospital, 82
- Manohar, B. N., 235
- Professor Manote, 140–141
- manufacturing, 250
 - facility construction in, 249
- markets, 26, 31, 259–260
 - absence of regulation for, 131
 - automation and, 144
 - Depuy on, 271
 - distancing mechanism of, 248
 - ethics and, 96
 - innovative acceleration and, 51–52
 - Japanese–Thai collaboration and, 132, 144
 - national permission for, 49
 - neoliberalism and, 33–36
 - PMDA and, 158
 - product functionality and, 85
 - R-CPX and, 139
 - responsive-market tools and, 5
 - scientific applications and, 159
 - social contract and, 258
 - Stempeutics and, 87
 - time-limited authorisation and, 224
- Martin, Emily, 92
- Marxism, 34
- Masayo, Takahashi, 165
- Master, Z., 122
- Medical Council of Thailand (MCT), 130, 140–142
- medical device regulation, 62
- Medical Practitioners Act (Japan), 223, 232
- Medical Research Council (MRC) (UK), 238
- medicinal signaling cells, 104
- Medicines Adaptive Pathways to Patients (MAPPs), 51, 119
- Medicines and Healthcare products Regulatory Agency (MHRA) (UK), 227
 - Early Access to Medicine Scheme and, 51
- Melton, Doug, 215, 237
- Memorandum of Understanding (MOU), 197–198

- mesenchymal stem cells (MSCs),
 - 10–11, 104–105
 - national income and, 99
 - patient funding and, 117
 - safety and, 104–105
 - Tianjin stem cell cluster and, 72
 - upscaling and, 130
- mesenchymal stromal cells, 104
- Mesoblast, 59
- Metchnikoff, Elie, 92
- methodology, 21–23
- Michael J. Fox Foundation for
 - Parkinson's Research (MJFF), 254
- military research, 70, 72–73
 - immunity metaphors and, 92
- mimetic desire, 243
 - Others and, 211
- mimetic principle, 31
- mimetic rivalry
 - caring solidarity and, 270
 - competition and, 100
 - competitive desire and, 97
 - discursive messaging and, 96
 - regulatory immune-tolerance and, 95
 - regulatory immunity and, 93–98
 - scapegoating cultures and, 103
- mimetic theory, 212–213
 - creative desire and, 265
 - creative mimesis and, 263–264
- minimal manipulation, 53, 117–118, 235
- Ministry of Economy, Trade and
 - Industry (METI) (Japan), 157, 233
- Ministry of Education (China), 74
- Ministry of Education, Culture, Sports,
 - Science and Technology (MEXT)
 - (Japan), 157, 160, 164
- Ministry of Health (MoH) (China), 67–68
 - hESR guidelines and, 102
 - January 2012 Notification by, 73
 - PLA and, 72
 - Tianjin UCB and, 71
- Ministry of Health, Welfare and Labor
 - (MoHWL) (Japan), 58, 142, 157–158, 195
 - competition and, 234
 - global brokerage and, 230
 - Parkinson's Disease and, 170
 - PMD pathway and, 169
 - Takahashi and, 163
 - whole-genome sequencing costs and, 170
- Ministry of Science and Technology
 - (MoST), 70
- minor histocompatibility antigen
 - (MHA), 170
- Mirowski, P., 159
- misrecognition, 31
 - AJS and, 155, 163, 165, 177–178
 - international brokerage and, 228
 - life-saving medicine and, 211
 - politics of, 156
- misrepresentation, 264
 - misrecognition and, 228
- modernity, 112–113
- monopoly, 3, 9, 34
- morally binding action, 267–268
- multi-centre clinical trials, 55
- Multi-Stem, 50
- muscular dystrophy (MD), 30, 185–188
 - diverse needs of disabled and, 190–192
 - embodied identities and, 204
 - industry collaboration and, 197–198
 - knowledge activism and, 200–202
 - locally situated demands and, 193, 195–196
 - patient movements and, 183
 - political governance and, 186–188, 190
- muscular skeletal disorders, 175
- mutations, 170
- mutual surveillance, 118
- mutuality, 26, 74
 - CRT participation and, 258
 - Depuy and, 271
 - good governance and, 257
 - market/gift exchanges and, 260
- Dr Nakasone, 138
- Nakauchi, Hiro, 160
- Doctor Nantakam, 137, 140–141
- National Apex Committee for Stem
 - Cell Research and Therapy (NAC-SCRT)(India), 52, 80, 219, 235
- National Center for Child Health and
 - Development (Tokyo), 133
- National Centre for Human Stem Cell
 - Research Engineering (NC-SCRE), 76

- National Development and Reform
Commission (China), 71, 76
- National Ethics Committees, 57
- National Guidelines for Stem Cell
Research (2013) (India), 80–81, 219
- National Guidelines for Stem Cell
Research (2017) (India), 234–235
- National Health and Family Planning
Commission (NHFP), 67–68
- National Health Commission (NHC)
(China), 237
- National Health Service (NHS) (UK),
51, 101, 238
- National Institute for Health and Care
Excellence (NICE), 51
- National Institute for Health and Care
Research (NIHR) (UK), 101
- National Institute of Advanced
Industrial Science and Technology
(NAIST), 133
- National Institute of Health (NIH)
(Japan), 225
- National Institute of Health (NIH)
(Korea), 232
- National Institute of Health (NIH)
(USA), 53, 109
Clinicaltrials.gov database, 115
funding by, 223
- National Key Research and
Development Program ‘Stem Cell
and Transformation Research’
(China), 237
- National Medical Products
Administration (NMPA) (China),
237
- National Organization for Rare
Disorders (NORD), 254
- National Stem Cell Engineering
(NSCE) Industrialization Base, 71
- nation-states, 38
cost-benefit analysis and, 248
globalisation and, 246–248
immunity metaphors and, 92–93
monopoly and, 3
policy formation and, 45–47
power and, 94
regulatory boundary-work and, 28,
44–45
regulatory gaps and, 206
regulatory governance and, 5
regulatory immune-tolerance and, 95
Self and, 29
social contract and, 257
state support brokerage, 217, 219–221
support for investment by, 249–250
transcendental authority and, 260
trust and, 205
See also regulatory governance
- Nature Cell, 234
- negotiation, 145
collaboration and, 127–128
levels of organisation and, 216
regulatory brokerage and, 239
regulatory capital and, 126
- neoliberalism, 4
FTCM and, 181
outsourcing regulation and, 215
regulatory boundary-work and, 64
regulatory capitalism and, 33–36
- Netherlands, 118, 183
- networks, 18
alternative therapeutic practices and,
63
biomedical platforms and, 82
case-studies of, 19
complexity of, 70
entrepreneurism and, 82
funding through, 72
Guangzhou Alliance and, 74–75
regulatory boundary-work and, 60–62
regulatory orientation and, 77–78
Zhao access to, 71. *See also* health
organisations; organisational
levels; patient organisations
- Neuralstem, 73
- Neurogen, 50, 235
- neurorestorative therapies, 61
- New Drugs and Clinical Trial Rules
(India), 235
- Niscell, 56
- non-disclosure agreements (NDA), 223
- non-governmental organisations
(NGOs), 188
- non-homologous use, 113
- non-political organisations (NPOs), 188
- non-routine use, 53

- Non-Self, 29
- Norio, Nakatsuji, 175
- normalcy, 204, 254
- North America, 114
- 'Notification on Self-Evaluation and Self-Correction Work regarding the Development of Clinical Stem Cell Research and Applications' (MoH 2011), 68, 298
- Novartis, 249
- Novumcella, 235
- objectification, 263–265
- Office of Medical Innovation (Japan), 221
- off-the-shelf therapies, 171
 - AJS and, 178
 - state investment and, 249
- Okano, Hideyuki, 160
- Okano, Teruo, 221–222
- oligopoly, 34
- oocyte sourcing, 11, 176
- opportunistic regulatory brokerage, 210–212, 216–217, 219, 224, 239
 - slow science and, 214
- organ bioengineering, 101
- Organisation for Economic Co-operation and Development (OECD), 4
- organisational level. *See also* health organisations; networks; patient organisations.
- organisational levels, 216
- orientations. *See* regulatory orientation
- Orphan Drug Designation (ODD), 50
- Osaka Declaration, 222
- Osiris, 74
- osteoarthritis, 58, 125, 133, 135, 142–143
- osteoporosis, 252
- Other-ability movement, 184
 - normalcy and, 204
- Othering, 264–265
- Others, 26, 92, 211
 - immunity metaphors and, 92
 - snake-oil and, 42
- pain management, 187, 192
- Pal, Ratan (pseudonym), 81–82
- parent organisations, 187
- Parents of Patients with Muscular Dystrophy Organization (PPMDO), 187
- Parkinson's Disease, 105, 169–170, 178
 - small-scale studies and, 107
- parliamentary discussion, 248
- Patel, Lord Kamlesh, 251
- Patent Act (Japan), 158
- patient choice, 107, 111
- patient confidentiality, 110
- patient engagement, 257–258
- patient financial contributions, 106
 - Australia and, 117
 - Beike and, 109, 111
 - ethicality of, 107
 - US and, 114–115
- Patient For Stem Cells, 115
- patient movements, 30
 - Deane-Drummond and, 266
 - deregulation and, 154
 - experimentation and, 205–206
 - HOs and, 181–184, 186, 189, 193–195
 - knowledge activism and, 199–200
 - regulatory brokerage and, 207
- patient needs, 42
 - AJS and, 174, 178
 - AJS lack of priority for, 164
 - caring solidarity and, 214, 240
 - CGTs and, 227
 - disability and, 190–193
 - down-regulation and, 184
 - global sharing of, 204
 - local communities and, 268
 - misrecognition and, 31, 153, 228
 - political desirability of, 104
 - regulatory tolerance and, 121
 - regulatory violence and, 2, 185
- patient organisations: *See also* health organisations; networks; organisational levels
- patient rights, 202
- patients, access to, 260–263
- Pei Duanqing, 74
- Peking Union Medical College (PUMC), 71
 - collaboration with, 76
 - Institute of Hematology of, 71–72

- People's Liberation Army (PLA), 73
 - 307 Hospital patients at, 70
- performance, 20, 23, 25, 150–151, 154, 207
 - All Japan System and, 30, 154
 - international dynamics of, 209
 - political movements and, 19, 31, 52
 - regulation as, 7
 - regulatory boundary-work and, 99
 - regulatory brokerage and, 217
 - regulatory change and, 18
 - regulatory discrepancies and, 245
 - regulatory flexibility and, 5
 - regulatory redemption and, 151
 - varying enactments of, 149
- permissive regulation, 113
 - AJS and, 178–179
 - Australia and, 116–117
 - HOs and, 205
 - Japan and, 224
 - Japanese–Thai collaboration and, 144
 - prohibitive regulation and, 239
 - regulatory brokerage and, 210, 239
- Pfizer, 176
- Pharmaceutical Affairs Law (PAL), 58
- Pharmaceutical and Medical Drugs
 - Agency (PMDA) (Japan), 133
- pharmaceuticals, 16–17, 101, 143, 205
 - Chinese classification as, 68
 - FTCM and, 181
 - HOs and, 198
 - industrial standards and, 176
 - lowering costs and, 183
 - monopoly of, 205
 - rogue practices and, 197
 - takeover targets and, 249
- Pharmaceuticals and Medical Devices
 - Agency (PMDA)(Japan), 58, 159, 169–170
 - global brokerage and, 229–230
 - GMP and, 173
 - INDs and, 173
 - internationalisation and, 177
 - Japanese–Thai collaboration and, 145
 - Kanagawa Centre and, 226
 - patient financial contributions in, 106
 - predatory firms and, 234
 - product approvals and, 180
 - Taiwan and, 236
 - time-conditioned approvals and, 241
- Pharmaceuticals, Medical Devices, and
 - Other Therapeutic Products Act (PMD Act), 58
 - international brokerage and, 225
 - JSRM and, 222
 - Parkinson's Disease and, 170
 - regulatory immunity and, 240
 - state investment and, 252
- phase three trials, 181
- phase two trials, 181
- physical exercise, 195
- placebos, 55, 107, 110
- Plan for the Promotion of Medical
 - Research and Development, 219
- platelet production, 173
- pluripotent stem cells (PSCs), 10
 - classifications of, 175–176
 - iPSCs and, 11–12
 - ISCBI and, 174
 - upscaling production and, 249
- Poland, 120
- Polanyi, Michael, 34
- policy formation, 45–47
- political desire, 121
 - experimentation and, 105
 - regulatory harmonisation and, 103
- politics, 23–25, 29, 151, 186–190
 - AJS and, 156, 163, 174, 177–178
 - effectiveness in, 258
 - formation of political society and, 257
 - globalisation and, 246–248
 - HOs and, 204
 - identity and, 203, 206
 - misrecognition and, 152–153
 - regulatory boundary-work and, 52
 - regulatory immunity and, 245
 - regulatory redemption and, 149–155
 - social contract and, 258–259
 - See also* regulatory boundary-work
- polycentric regulation, 4
- pop-up markets, 107
- poverty, 203, 261

- power, 157
 - AJS and, 168
 - nation-states and, 94
 - regulatory redemption and, 129, 150
 - transcendental forms of, 70
 - transfer of, 247
- pragmatism, 203
 - trial design and, 262
- pre-market authorisation, 114
- prenatal genetic testing, 187
- primary care, 268
- primary prevention of medical conditions, 268
- Priority Medicine (PRIME), 119
- private interest theories, 6
- privatisation, 35
- product functionality, 85
- production, 53, 101
 - dialectic of, 150–151, 155, 163
 - global expansion of, 35
- profit, 107
 - caring solidarity and, 270
 - high-risk strategies and, 246
 - political desire and, 105
- prohibitive regulation, 113
 - active brokerage and, 221
 - FTCM and, 183
 - Japan–Thailand collaboration and, 128
 - opportunistic brokerage and, 239
 - regulatory brokerage and, 210, 217
 - regulatory immunity and, 240
- Promising Innovative Medicine (PIM) designation, 51
- protectionism, 34
- prudence, 27, 32, 214, 263
 - caring solidarity and, 212, 270
 - common good and, 265–266
 - local notions of wisdom and, 246
 - utilitarianism and, 269
 - wisdom and, 268
 - See also* caring solidarity
- Prudent Healthcare, 266
- public choice theory, 6
- public discussion, 22
- public interest theories, 6
 - regulatory reputation and, 91
- public needs, 45
- publication of research, 134
- pure vs. applied science, 159
- Quality Control Standards for Clinical Drug Trials' (CFDA), 67
- race, 262
- radical regulatory change, 42, 47, 58–60, 63
 - AJS and, 162
 - South Korea and, 64
- randomised control trials (RCTs), 53–55
 - adverse effects and, 106
 - ethical appraisal of, 107–108
 - kosher/rogue binary and, 103
 - poor insurance conditions and, 202
 - universal regulation and, 105–106
 - See also* clinical research trials (CRTs)
- rare disease criteria, 50
- rational individualism, 263
- RBio, 234
- reactive brokerage, 224, 231
 - forms of, 217
- reconstructive procedures, 84–85
- recruiter patients, 182
- Red Cross, 138
- red envelopes (bribes), 111
- redemption. *See* regulatory redemption
- reform. *See* regulatory reform
- regenerative medicine, 10–13, 165, 176–177
 - experimental therapy, 16–18
 - foreseeable harm and, 1–2
 - global dynamics of, 18–19
 - investment in, 13–14
 - See under* regulation
- Regenerative Medicine* (journal), 117
- Regenerative Medicine Expert Group (House of Lords, UK), 238
- Regenerative Medicine
 - Industrialization Task Force (RMIT), 226
- Regenerative Medicine Law (Japan), 238
- Regenerative Medicine Markets
 - Analysis and Forecast, 13
- Regenerative Medicine Promotion Act (RMP Act), 222, 241, 258
- Regenerative Sciences, 104

- Regenexx, 104, 115
- registries, 200–202
- REGROW-Act (USA), 232, 235, 241
- regulation, 3, 14
 - alternative forms of, 15
 - Black on, 215
 - change process and, 20
 - definitions of, 4
 - experimental practices and, 16–18
 - global dynamics of, 18–19
 - Japanese–Thai collaboration and, 140–143
 - multiple pressures on, 7
 - neoliberalism and, 4–5
 - rebellion against dominant modes of, 60
 - regulatee binary and, 7
 - regulatory violence and, 21
 - scientific rationale of, 28
 - theories of, 5–7
- Regulation on the Review and Authorization of Biological Products (South Korea), 57
- regulatory acceleration, 48
 - Australia and, 118
 - exemptions and, 205
 - fast-track approval and, 57
 - HOs and, 190
 - PMDA and, 180
 - R-CPX and, 142
 - regulatory brokerage and, 210
 - US and, 114–115
- regulatory adjustment, 46, 118, 231, 240
- regulatory agencies, 107
- regulatory assets, 136
- regulatory authority, 48
- regulatory boundary-making, 29
 - caring solidarity and, 270
 - international brokerage and, 228
 - Japanese style of, 219
 - performance and, 149
 - scapegoating and, 97
- regulatory boundary-work, 23, 25, 37–42, 62–64
 - authority and, 48–49
 - collaboration and, 124
 - ethical binaries and, 123
 - factors underpinning, 59
 - HICs and, 121
 - innovation and, 52
 - international networks and, 60–62
 - Japanese–Thai collaboration and, 144
 - LMICs and, 78, 88–89
 - local contexts for, 52
 - national conditions and, 45–47
 - nation-state politics and, 28
 - politics of reputation and, 91–92
 - RCTs and, 55
 - regulatory concepts and, 211
 - regulatory immunity and, 28, 99
 - regulatory orientation and, 89
 - regulatory reputation and, 102
 - scientific boundary-work and, 42–44
 - state governance and, 44–45
 - strategic practices of, 27
 - West and, 113
- regulatory brokerage, 3, 23, 25, 27
 - AJS and, 162, 180
 - down-regulation and, 254
 - five forms of, 216–217
 - foreseeable harm and, 215
 - global brokerage and, 228–231
 - harmful consequences of, 243
 - illegitimate aims of, 246
 - illegitimate reasons for, 244
 - informal forms of, 217–219
 - international form of, 224–228
 - justice and, 269
 - marginal standards and, 35
 - neoliberalism and, 33
 - organisational levels of, 216
 - prohibitive regulation and, 239
 - reform and, 221, 224
 - regulatory boundary-work and, 46
 - regulatory capacity building and, 28
 - regulatory capitalism and, 64
 - regulatory difference and, 245
 - regulatory discrepancies and, 239
 - regulatory immunity and, 89
 - regulatory redemption and, 150, 153
 - regulatory violence and, 31, 209–212, 242–243
 - research therapy tension and, 15
 - state support and, 219–221

- regulatory capacity building, 23, 25, 28, 30
 - China and, 67–69
 - competition and, 88
 - hegemony and, 89
 - India and, 80
 - Japanese–Thai collaboration and, 144
 - LMICs and, 66
 - prohibitive regulation and, 240
 - regulatory concepts and, 211
 - regulatory orientation and, 77–78
 - Stempeutics and, 83–84, 87
 - See also* regulatory orientations
- regulatory capital, 29
 - active brokerage and, 221
 - centrality of, 29
 - collaboration and, 125–126
 - commodification and, 239
 - international brokerage and, 225, 228
 - Japanese reform and, 224
 - Japanese–Thai collaboration and, 127–128, 133, 143–147
 - regulatory brokerage and, 209
 - regulatory concepts and, 211
 - regulatory difference and, 245
 - regulatory immunity and, 240
 - state support brokerage and, 219–221
- regulatory capitalism, 2, 4–6, 15, 25–27
 - Beike and, 111
 - caring solidarity and, 31, 270–271
 - collateral sacrifice and, 248
 - commodification and, 263
 - competitive advantages under, 123
 - competitive strategies and, 246
 - conceptual terminology of, 23
 - creative desire and, 263
 - global brokerage and, 231
 - global dynamics of, 18–19, 204
 - globalisation and, 247
 - immunity metaphors and, 92
 - Japanese–Thai collaboration and, 147
 - large LMICs and, 108
 - LMICs and, 88
 - local communities and, 243
 - mutuality and, 257
 - neoliberalism and, 33–36
 - patient movements and, 30
 - patient populations and, 260, 262–263
 - political movements and, 154
 - regulatory boundary-work and, 39–40, 64
 - regulatory brokerage and, 213
 - regulatory immune-vacuum and, 93, 96–97
 - regulatory immunity and, 94
 - regulatory redemption and, 150
 - regulatory reputation and, 37–38
 - regulatory theories and, 216
 - social contract and, 243, 246, 256, 259–260
 - stem cell trials and, 13
 - theory of, 5
 - Regulatory Capitalism* (Braithwaite), 35
 - regulatory capture theory, 6, 40, 215
 - regulatory cascades, 208, 212, 215–216, 231
 - regulatory competition, 2, 27
 - China and, 237
 - global dynamics of, 18
 - increase in collaboration and, 42
 - mimetic desire and, 31
 - regulatory compromise, 3
 - regulatory consciousness, 245
 - regulatory contagion, 147
 - regulatory convenience, 79
 - regulatory development, 85, 87
 - global dynamics of, 28, 89
 - LMICs and, 88
 - regulatory difference, 211, 266
 - Japan and, 234
 - local dilemmas and, 66
 - regulatory brokerage and, 245
 - regulatory capital and, 245
 - Stempeutics and, 87
 - regulatory discrepancies, 31, 40, 97, 152, 239, 242
 - agency and, 208
 - AJS and, 155
 - collaboration and, 216
 - competitive desire and, 213
 - Japanese–Thai collaboration and, 125–127, 130, 143, 145–146
 - parallel studies and, 228
 - performance and, 245

- reactive brokerage and, 224
- regulatory brokerage and, 217–218
- regulatory capital and, 209
- regulatory immunity and, 125
- regulatory diversity, 63
- regulatory facilitation, 153
 - affordability and, 253
 - misrecognition and, 153
- regulatory flexibility, 145
 - COVID-19 and, 214
 - performance of, 5
- Regulatory Framework for Biologics, 116–117
- regulatory governance, 5–7
 - frictions in, 26
- regulatory harmonisation, 91, 113, 174
 - Asian regulation and, 144
 - global brokerage and, 228, 230
 - Japan–UK and, 227
 - political desirables in, 103
 - Stempeutics and, 87
 - WHO and, 100
 - WTO and, 123
- regulatory hegemony, 28
- regulatory ideals, 101, 121
 - political desirability and, 104
 - RCTs and, 105, 107
- regulatory immune tolerance, 28, 91, 93–96
 - regulatory concepts and, 211
 - scapegoating and, 96–97
 - See also* regulatory immunity; regulatory tolerance
- regulatory immune-vacuum, 93, 96–98
- regulatory immunity, 24–25, 28
 - AJS and, 179
 - Beike and, 111–112
 - collaboration and, 126, 239
 - competitive desire and, 240
 - establishment of law and, 93–94
 - global brokerage and, 231
 - Japan and, 151, 155, 219
 - Japanese–Thai collaboration and, 147
 - politicisation and, 245
 - regulatory boundary-work and, 99
 - regulatory brokerage and, 197
 - regulatory concepts and, 211
 - regulatory discrepancies and, 125
 - regulatory immune-tolerance and, 91, 94–96
 - regulatory immune-vacuum and, 96–98
 - regulatory redemption and, 150
 - regulatory reputation and, 91–93
 - Self and, 101, 103
 - South Korea and, 233
 - time-conditionally-approved products and, 224
 - trust and, 234
 - universal regulation and, 106
 - US and, 114
 - weakness of, 240
- regulatory immunisation, 113, 120–122
 - down-regulation and, 205
 - HOs and, 206
- regulatory impasse, 47, 63, 112
- regulatory inflation, 66
- regulatory infrastructures, 261
- regulatory knowledge, 245
- regulatory loopholes, 114
- regulatory manipulation, 21, 35
- regulatory objectivity, 43
- regulatory orientation, 69–70, 211
 - China and, 71, 75–78
 - India and, 88–89
 - Stempeutics and, 78–79, 81, 85
 - See also* regulatory capacity building
- regulatory pathways, 87
- regulatory patterns, 244
- regulatory permission, 48
- regulatory politics, 62
- regulatory redemption, 23, 25, 30, 149–151, 153–154
 - All Japan System and, 155–156, 159–160, 162–163
 - deregulation and, 184
 - down-regulation and, 181, 184, 205
 - FTCM and, 186
 - Japan's 2013 reforms and, 30
 - misrecognition and, 153, 177
 - overhyped celebration of, 245
 - patient movements and, 30, 182
 - reform and, 224
 - regulatory concepts and, 211
 - Taiwan and, 236
 - transcendental force and, 151–152

- regulatory reform, 127, 210, 231, 239
 - AJS and, 160, 163, 166, 168–169
 - cascades of, 216
 - China 2009 regulations and, 67
 - Comprehensive Special Zones and, 225
 - India and, 86
 - ISSCR and, 229
 - Japan and, 221–224, 234
 - Japanese–Thai collaboration and, 147
 - overhyping iPS and, 179
 - performance of, 154
 - regulatory capital and, 146
 - regulatory redemption and, 155–156, 159
 - scientific reality of, 177
 - South Korea and, 233
 - Taiwan and, 236
 - US influence on, 231–232
- regulatory reproduction, dialectic of, 151
- regulatory reputation, 28, 91
 - Australia and, 117
 - constrictive regulation and, 149
 - discursive messaging and, 96
 - EU and, 118
 - ICMS and, 61
 - India and, 78, 87
 - investment and, 57
 - Japan and, 155, 224
 - Japanese reforms and, 154
 - Japanese–Thai collaboration and, 128, 132, 134
 - manipulation of, 210–214
 - national income and, 99
 - public interest and, 81
 - R-CPX and, 143
 - regulatory immunity and, 91–93
 - regulatory redemption and, 150
 - risks to, 101–103, 170
 - soft law and, 221
 - Stempeutics and, 85
- regulatory resistance, 79
- regulatory ritualisation, 24–25
 - misrecognition and, 153–154
 - R-CPX and, 147
 - regulatory redemption and, 152
- Regulatory Science Centre, 230
- regulatory sovereignty, 246
- regulatory space, 48
- regulatory state approach (Levi-Faur), 5
- regulatory tolerance, 28–29
 - Australia and, 116–117
 - Beike and, 108, 112
 - EU and, 120
 - HICs and, 112, 121
 - India and, 235
 - international brokerage and, 228
 - Japan–India collaboration and, 219
 - regulatory capital and, 147
 - regulatory immune-tolerance and, 94–96
 - regulatory redemption and, 150
 - risk differentiation and, 106
 - Self and, 101, 103
 - Therapeutic Goods regulation and, 122
 - universal regulation and, 99, 106
 - US and, 114–115, 240
- regulatory uncertainty, 18
 - medical device regulation and, 62
- regulatory violation, 8
- regulatory violence, 2–4, 24, 26–27
 - caring solidarity and, 269–270
 - competitive desire and, 31
 - creative desire and, 263–264
 - definitions of violence and, 7–9
 - down-regulation and, 30
 - foreseeable harm and, 1–2
 - global dynamics of, 20
 - globalisation and, 246–248
 - immunity metaphors and, 92
 - local communities and, 266–268
 - patients movements and, 31
 - politics vs. capitalism and, 216
 - regulatory brokerage and, 31, 209–213, 242–243, 245–246
 - regulatory immunity and, 93
 - regulatory redemption and, 30
 - research therapy tension and, 15
 - sacrifice of patient interests and, 248
 - sustainability of healthcare and, 21
- rehabilitation, 195
- reimbursement eligibility, 225

- Reliable and Effective Growth for
Regenerative Health Options that
Improve Wellness Act
(REGROW), 254
- Reliance, 56
- REMEDI, 119
- Remudy (MD-research collective), 195
- Reproductive & Genetic Hospital
CITIC-Xiangya, 75–76
- reputation. *See* regulatory reputation
- Research Institute of Economy, Trade
and Industry (RIETI), 233
- resistance, 44
- responsible innovation, 78–79, 81, 86
- responsive regulation, 215
- retinal pigment epithelium (RPE), 165,
167, 170–171
- ‘return to society’ aims, 187
- Revised Pharmaceutical Affairs Law, 158
- right to try laws, 15, 154
- RIKEN Centre for Developmental
Biology (CDB), 160, 163, 166
- closure of, 177
- rising powers, 42, 88–89
- risk-benefits analysis, 268–269
- risk-management, 224, 247–248
- differentiation of, 106
- high-profit margins and, 246
- industrial standards and, 176
- RNL Bio, 234
- RNL/Celltex, 53
- Roadmap for Regenerative Medicine,
141
- Robot Cultivate Cell Culture (R-CPX),
125–126, 128–130, 144–145
- Japanese–Thai collaboration and,
132, 145
- medical benefits of, 136–137
- proving worth of, 144
- regulation and, 140–143
- regulatory capital and, 143, 146–147
- scientific results of, 133–136
- trust in collaboration and, 137–139
- Robotic Stem Cell Incubation
Laboratory, 137
- rogue practices, 24–25, 29, 41, 63
- Beike and, 111
- discursive identification and, 97
- grey areas and, 95
- industry collaboration and, 197
- RCTs and, 103
- regulatory immunity and, 93
- regulatory reputation and, 102
- US and, 114–115
- X-Cell and, 118
- Roman law, 95
- rule by nobody, 9
- Russia, 42
- sacrificeable victims, 259–260
- same surgical procedure exception, 114
- Sasai, Yoshiki, 160
- Sawa, Yoshiki, 133, 135, 142, 222
- scaffolding, 135, 175
- Scandinavia, 183
- scapegoating, 29, 93, 96–97, 264
- caring solidarity and, 270
- cultures of, 102
- EU and, 120
- HICs and, 121
- Thailand and, 125
- SCI USA, 61
- science and technology studies (STS)
- approaches, 66, 78
- biomedical platform debates and, 89
- scientific atheism, 102
- scientific boundary-work, 37, 42–44
- scientific culture, 52
- scientific rationales, 89
- scientific results, 133–136
- differing priorities within, 143
- scientific uncertainty, 104
- stimulus to research of, 105
- SCI-Net, 67
- secrecy, 172, 178
- Seer, 75
- Self and Non-Self, 29, 92
- immunity metaphors and, 92–93
- mimetic rivalry and, 93, 100
- misrecognition and, 228
- regulatory tolerance and, 101, 103
- rogue competitors and, 97
- self-assessment, 61
- self-help, 74
- self-regulation, 94, 100, 103
- semi-private enterprises, 75–76

- Sendai virus, 172
- Sent, E. M., 159
- Sharma, Alok, 235
- Shenzhen (China), 109
- Shirai (immunologist), 174
- Shirakawa, 164
- Siebers, Tobin, 184
- Simons, Henry, 34
- Singapore, 57
 - Japanese–Thai collaboration and, 138
- Singh, Sanjay, 81–82, 85
- SiriCell, 57
- Sirindhorn, Crown Princess Maha Chakri, 138
- small-scale studies, 107
- Smith, Adam, 34
- snake-oil science and treatments, 24
 - Beike and, 111
 - EU and, 120
 - HICs and, 42
 - regulatory violence and, 8
 - Thailand and, 125
 - Traditional Chinese Medicine and, 102
- social care, 268
- social knowledge, 262
- social-contract, 246, 256–260, 271
 - investments too large to fail and, 256
 - Lancet Report and, 243
 - patient populations and, 262–263
 - sacrificeable victims, 259–260
- socio-economic environment, 261–262
- socio-political positions, 152
- socio-scientific network structures, 83
- soft law, 48
 - innovation and, 52
 - regulatory reputation and, 221
- somatic cell nuclear transfer (SCNT), 11
- somatic stem cell therapy, 10–12
 - dual-track system and, 237
 - EU and, 118
 - promise of, 143
- Dr Sombat, 134, 137–140, 142
- South Korea, 232–233
 - Australia and, 117
 - fast-track pathways and, 57–60
 - HOs and, 196, 205
 - India and, 235
 - industry collaboration and, 198
 - influence of reform and, 231–232
 - Japan and, 233
 - Japanese–Thai collaboration and, 138
 - knowledge activism and, 201–202
 - LMIC collaboration and, 57
 - market acceleration and, 51
 - regulatory boundary-work and, 64
 - regulatory dynamics of, 63
 - regulatory immunity and, 240
 - SCI and, 194–195
 - shared scientific cultures and, 53
 - stem cell trials in, 13
- Specials scheme (UK), 50
- Spinal Cord Injury (SCI), 30, 105, 185–186
 - diverse needs of disabled and, 190–192
 - HICs and, 196
 - HOs and, 182
 - identity politics and, 204
 - industry collaboration and, 197–198
 - knowledge activism and, 200–203
 - locally situated demands and, 192–195
 - patient movements and, 183
 - personal decision-making and, 255
 - political governance and, 186–188, 190
 - problems of global activism and, 203
 - self-empowerment and, 189
- Spinal Cord Injury Network (SCIN), 188, 194
- spotted regulatory brokerage, 26
- Sri Lanka, 188
- Srinivasan, Professor (pseudonym), 86
- stakeholders, 69, 150
- Stamina Foundation, 119–121
- standards, 43
 - deviant forms of, 52
 - See also* regulatory boundary-work
- Standards* (Busch), 34
- STAP-cells (Stimulus-triggered acquisition of pluripotency), 177
- Stem Cell and Cell Based Products (SCCPs) designation, 80
- Stem Cell and Regenerative Medicine Strategy Working Group, 160
- Stem Cell Network (Canada), 60
- Stem cell Network Asia Pacific (SNAP), 60
- Stem Cell Research Society of Thailand, 140

- stem cell science, 10–12
 - debating distinctions among, 103
 - limited expert knowledge in, 86
 - See also* clinical research trials (CRTs); *under*regulation
- stem cell tourism, 102
 - Beike and, 109
 - HOs and, 195
 - patient movements and, 182
 - R-CPX and, 136
- Stemgenex, 115
- Stempeucare, 83–85
- Stempeucel, 83–84
 - 2013 regulation and, 235
- Stempeutics, 56, 59, 66, 81–83, 85–87
 - 2013 regulation and, 235
 - allogeneic stem cells and, 81–83
 - formulating regulation and, 88
 - responsible innovation and, 78–79
 - three-fold plan by, 83–85
 - unauthorised clinics and, 81
- Stempeutron, 83–85
- Stengers, Isabelle, 214
- strict regulation, 205
- structural factors, 247, 269
- structural violence, 8–9, 242
- subsidiarity principle, 118
- Sumitomo Dainippon Pharma Co, 170–171
- Sun Yat-Sen University, 77
- Sūpā Tokku (special disciplinary areas or networks), 158
- sustainable health, 2, 32, 246, 263
 - caring solidarity and, 270
 - Japan and, 267
- symbolism, 149
 - All Japan System and, 154, 168
 - R-CPX, 147
 - regulatory redemption and, 150–152
 - saving lives and, 153
- Taiwan, 53, 236–237
- Taiwan Association for Cellular Therapy, 236
- Taiwan Department of Public Health, 236
- Taiwan Food and Drugs Administration (Taiwan FDA), 236
- Takahashi, Jun, 169–170
- Takahashi, Kazutoshi, 11, 156–157
- Takahashi, Masayo, 163, 166–168, 170–171
 - Healios and, 177
- Takayama, Kazuo, 163
- Tanabe, Koji, 169–170
- Tanida (tissue engineer), 175
- TEDA development zone, 71
- Temcell, 225
- Temple, Sally, 235
- Terumo, 222, 225
- Texas (US), 53
- THAI [pseudonym]), 125, 128, 131
 - R-CPX and, 136, 145
 - regulation and, 141
 - regulatory capital and, 147
 - regulatory reputation and, 134
 - trust and, 139
- Thai Food and Drug Administration (TFDA), 131, 138, 142–143, 145
- Thai Physician Association (TPA), 140
- Thai Revised Drug Act, 144
- Thailand, 131, 138, 142–143, 145
 - 2009 regulation and, 130
 - caring solidarity and, 241
 - collaboration with, 124–127
 - investment by, 56–57
 - patient populations and, 262
 - regulatory boundary-work and, 64
 - regulatory immunity and, 240
 - shared scientific cultures and, 53
 - state support brokerage and, 219–221
- thalassemia, 124, 136–137
- The Automation Partnership Biosystems (TAP Biosystems), 129
- therapeutic goods, 116–117, 121
- Therapeutic Goods Association (TGA), 117
- therapy provision, 80–83, 85–86, 88
 - Beike and, 110
 - R-CPX and, 136–137
 - regulatory immunisation and, 121
 - risk and, 135
 - symbolic value of saving lives in, 139
 - tension between clinical research trials and, 14–15

- TheraVita, 57
 Thomson, James, 11, 157
 351 products, 114
 361 products, 113
 Tianjin Amcell Gene Engineering Co., Ltd., 72
 Tianjin Huayuan Hi-tech Park, 71
 Tianjin Municipality, 70–72
 Tianjin Umbilical Cord Blood Bank, 71
 Tianjin Xiehe hospital, 72
 tiered payment systems, 198. *See also* healthcare insurance
 tiered risk system, 224
 TiGenix, 50
 time-conditioned approval, 224, 229
 RMP and, 241
 Taiwan and, 236
 tissue engineering, 175
 tissue regeneration, 84
 tissue-engineering centers (TECs), 74
 Toda, Yuzo, 230
 Tokyo University, 160
 tolerance. *See* regulatory tolerance
 Too Much Medicine, 266
 Tooke, Sir John, 251
 top-down approaches, 215
 Trade Related Aspects of Intellectual Property Rights (TRIPS), 36
 Traditional Chinese Medicine (TCM), 102, 192
 transcendental authority, 96, 151–152
 caring solidarity and, 269
 social contract and, 260
 translational research, 17, 39–40, 55
 acceleration of, 51
 AJS and, 179
 bodily violence and, 247
 competitive desire and, 251
 credible authority and, 97
 FDA and, 49
 House of Lords and, 251
 India and, 78, 82, 88
 LMICs and, 56
 medium-sized countries and, 57
 regulatory brokerage and, 210
 regulatory redemption and, 153
 social contract and, 256
 state investment and, 252
 transparency, 72
 trial design, 51
 AJS and, 173–174
 deficiencies in, 179
 local conditions and, 262
 triangular mimetic desire, 26–27, 31
 trust, 137–139
 HOs and, 194–195, 197–198
 individual-rights discourses and, 203
 Japan and, 234
 Japanese–Thai collaboration and, 143
 state regulators and, 205–206
 Tsai, T.-H., 236
 tumorigenicity, 12
 21st Century Cures Act, 232
 2001 moratorium on federal funding for human embryonic stem cell (hESC), 41
 UK–JAPAN Life Innovation Symposium, 226–228
 umbilical cord blood banks (UCB), 71–72, 76
 Beike and, 110
 umbilical cord mesenchymal stem cells (US-MSCs), 108–109
 unauthorised practices, 16
 Beike and, 111
 closing clinics and, 103
 formulating regulation and, 88
 HOs and, 205
 R-CPX and, 140
 regulatory tolerance and, 107, 240
 Stempeutics and, 87
 US and, 114–115
 unclear/developing regulation, 47
 unethical practices, 22
 collaboration on, 147
 universal application and, 106
 Union Stem Cell & Gene Engineering (USCGEN), 71–72
 United Kingdom (UK), 197, 226–228
 competition and, 101
 Early Access to Medicine Scheme in, 51
 HO resource competition in, 188
 House of Lords debate in, 251–252
 industry collaboration and, 198

- Japan and, 238
- Japanese investment and, 223
- needs of disabled and, 191
- SCI and, 193, 200
- soft law and, 48
- 'Specials scheme' in, 50
- United Kingdom Nuffield Council on Bioethics, 17
- United Kingdom Research and Innovation (UKRI), 112
- United Nations (UN), 267
- US Congress, 51
- US Court of Appeals, 114
- US Federal Trade Commission (FTC), 122
- US Food and Drug Administration (FDA), 113–115
 - accelerated approval and, 51
 - Biologics and, 116
 - compassionate treatment and, 50
 - conditional approval and, 254
 - direct-to-consumer and, 122
 - expanded access and, 115
 - forms of authority used by, 49
 - FTCM and, 181, 232
 - ICMS and, 61
 - IND programme and, 49
 - Japan and, 151
 - knowledge activism and, 200
 - minimal manipulation and, 53
 - Orphan Drug Designation and, 50
 - patient financial contributions in, 106
 - RCTs and, 55
 - Regenexx-C and, 104
 - right to try laws and, 15
 - same surgical procedure exception and, 114
 - scarcity of resources and, 39
 - unproven stem cell therapies and, 236
 - WHO and, 123
- United States of America (US), 113–115, 121–123
 - allogeneic stem cells and, 81
 - Australia and, 116–117
 - competition with Japan and, 233
 - conditional approval and, 254
 - ethical funding halt in, 101
 - EU and, 120
 - FTCM and, 181
 - HOs and, 205
 - India and, 80, 235–236
 - INDs and, 223
 - industry collaboration and, 197
 - influence of reform in, 231–232
 - international patient movements and, 154
 - knowledge activism and, 200, 202
 - market acceleration and, 51–52
 - minimal manipulation and, 53
 - modernity and, 113
 - off-label use in, 49
 - opposition to cooperation with, 177
 - patient financial contributions in, 106
 - patient movements and, 183–184
 - piecemeal regulation and, 59
 - platelet donations in, 173
 - private interest theories in, 6
 - pure science and, 159
 - RCTs and, 53–55
 - REGROW Bill and, 241
 - regulatory boundary-work and, 42
 - regulatory dynamics of, 63
 - regulatory overhaul and, 42
 - SCI and, 194–195
 - soft law and, 48
 - standards set by, 67
 - state funding and, 223
 - state investment and, 251
 - Stempeutics and, 86
 - UK–Japan collaboration and, 227
 - unauthorised stem cell-provision and, 240
 - Yamanaka and, 168
- universal prohibition, 111
- universal regulation, 102–103, 105–107
 - China and, 122
 - pluripotency and, 175
- University for Pregnant Women, 71
- University of Texas MD Cancer Anderson Centre, 56
- University of Wisconsin, Madison, 157
- university-linked alliances, 74
- unproven stem cell therapies, 235
- unrealistic hopes, 259

- upscaling production, 130
 - cost-benefits of, 256
 - Japan and, 229
 - R-CPX and, 137
 - state support brokerage and, 221
- US Stem Cell, 115
- US Stemology, 114
- utilitarian approaches, 269
- Valley of Death, the, 17
- venture capital, 223–224, 249
 - developmental pathway length and, 227
- victims, 264
 - sacrificeability of, 259–260
- Vietnam, 56–57, 64
- Dr Vimal(pseudonym), 86
- violence, 7–8
 - alternative methods and, 63
 - caring solidarity and, 270
 - cycles of revenge and, 259
 - definitions of, 7–9
 - establishment of law and, 93–94
 - exteriorisation of, 96
 - psychological forms of, 8
 - regulation and, 21
 - social contract and, 256
 - See also* regulatory violence
- virtue ethics, 266, 268–269
- Waseda University, 218
- wealth, 62
 - community and, 264
 - political identity and, 204
 - See also* high-income countries (HICs)
- Weber, Max, 3
- WeChat (weixin), 194
- well regulated countries, 113
- Wen Jiabao, 110
- Western society, 15, 41, 112–113
 - down-regulation and, 184
 - HOs and, 186, 193, 205
 - knowledge activism and, 199
 - patient movements and, 182
 - political influence of, 188
 - SCI and, 186, 194
 - Western-hegemony theory and, 38, 40
- Wharton's jelly cells, 120
- wheelchair access, 191, 195, 197
- whole-genome sequencing, 170
- Dr Wilipana, 135, 138–141, 221
- Willis, George Philip, Lord of
 - Knaresborough, 251
- Windholz, Eric, 5–6
- wisdom, 268, 270
 - local notions of, 246, 263
 - prudence as, 266
- Wise Young, 61
- women, expectation to care and, 192
- workspaces, 188–190
 - cultural politics and, 196
 - health activism and, 204
- World Health Organization (WHO), 100, 122–123
 - universal health coverage and, 267
- World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects (WMA 2018), 50
- World Premier International Research Centre Initiative (WPI), 164
- World Trade Organization (WTO), 36, 123
- Wu Medical Centre, 57
- Wu Zuke, 76
- X-Cell, 118
- Xi Jinping, 112
- Xiang Hu, 112
- Xiangya Reproductive Hospital, 75
- Yamanaka assays, 169
- Yamanaka methods, 178–179
- Yamanaka, Shinya, 11, 134, 156–157
 - AJS and, 160
 - doubt spread by, 175
 - Nobel Prize for, 136
 - product standardisation and, 174
 - Sendai virus and, 172
 - state investment and, 250
 - Yamanaka assay and, 167–169
- Yao-Chan Chen, 236
- Yokohama Declaration, 222–223
- Z Centre for Regenerative Medicine (ZCRM), 218–219
- Zhao Chunhua, 70–71, 76
- Zhejiang University, 70
- Zhongyuan Union Stem Cell Bioengineering Corporation, 56, 112